Albert Bourla, the boss of the $150 billion pharmaceutical giant Pfizer, admits leaders don’t win by always being right—the ...

The pharma company had to scale vaccine production from 200 million annually to 3 billion at the pandemic's peak.

Also: All the news and watercooler chat from Fortune.

Pfizer Inc. (NYSE:PFE) is included among the Dividend Champions, Contenders, and Challengers List: 15 Highest Yielding Stocks ...

Pfizer made one thing clear this week: It's officially back in the obesity race.

Pfizer (PFE) CEO Albert Bourla said he's learned to work with some unlikely allies — even those who once questioned the very foundation of his business. "Clearly, that was not going to be my choice ...

SAN FRANCISCO, Jan 12 (Reuters) - Pfizer is preparing for ‌a consumer market for obesity drugs on ‌par with the booming business it saw after it launched erectile dysfunction drug Viagra in 1998, CEO ...

Pfizer CEO Albert Bourla on Tuesday said uncertainty around President Donald Trump's planned pharmaceutical tariffs is deterring the company from further investing in U.S. manufacturing and research ...

Pfizer (PFE) chairman and CEO Albert Bourla joins Julie Hyman on Market Domination to talk more about the pharmaceutical ...